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Obesity is a growing problem and has signiﬁcant implications for a variety of diseases, including human
cancers. A positive association between obesity and incidence of many gynecological cancers, including
endometrial cancer, ovarian cancer, and breast cancer has been observed. The mechanism proposed to
connect obesity and these cancers was sex hormone, insulin resistance, and certain adipokines. Obesity
adversely affects survival in most studies. For endometrial cancer, the obesity was associated with
increased risk and unfavorable outcome. With regard to ovarian cancer and cervical cancer, the evidence
was inconsistent. The positive association between obesity and the risk of postmenopausal breast cancer
has been consistently observed but it is not the same story in premenopausal breast cancer. But the
prognosis for both pre- and postmenopausal breast cancer was substantially worse among obese than
normal-weight individuals. In this article, we review the current evidence linking obesity with risk and
outcome of gynecological cancers.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Currently, obesity has become a major public issue in most
developed and developing countries. Overweight and obesity have
been known to be associated with the risk of cardiovascular disease
and type 2 diabetes mellitus. More recently an epidemiological
connection between obesity and the prevalence of a variety of
cancers has been revealed. A body mass index (BMI) > 30 is asso-
ciated with increased risk for many female cancers, including
endometrial, gallbladder, esophageal, renal, leukemia, thyroid, and
breast cancers.1 Obesity also increases cancer-related morbidity
and mortality. In esophageal cancer, the increased risk may be
associated with the increase of acid reﬂux from obesity leading to
chronic local inﬂammation, Barrett's, esophagus, and eventually
adenocarcinoma.2 Colon cancer has been known to associate with
high caloric intake and low ﬁber diet. The energy balance and BMI
are intricately connected with diet content.3,4 There is increasing
awareness of the effect obesity also may have on cancer, as new
evidence suggests that overeating along with obesity may be the
largest preventable causes of cancer among nonsmokers and may
account for one in ﬁve cancer deaths among women.5 A higher BMIof interest in this work.
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may have shorter survival secondary to delay in cancer screening or
suboptimal dosage of chemotherapy.6,7 Several mechanisms have
been proposed to link the association between obesity and cancer
promotion including insulin resistance, estrogen, adiposity, and
low-grade chronic inﬂammation.8 Here we review the literature to
identify the effect of obesity on several gynecologic cancers.
Obesity and endometrial cancer
Incidence rates of endometrial cancer are much higher in
Western countries than in Asia or rural Africa.9 The evolution of the
industrial development and migration from low- to high-risk areas
has shown that endometrial cancer has strong environmental or
nongenetic risk factors. Several risk factors have been proposed,
including postmenopausal unopposed estrogen use, nulliparity,
diabetes mellitus, and obesity. Obesity has been estimated to ac-
count for up to 40% of endometrial cancer incidence in developed
countries.10 The interaction between obesity, estrogen, insulin
resistance, and carcinogenesis has been extensively investigated
(Figure 1). Adipose tissue converts androstenedione to estrone and
is a major source of circulating estrogen in postmenopausal
women. From the perspective of histological and molecular pa-
thology, at least two major subtypes of endometrial cancer can be
deﬁned. Type I cancers are categorized as endometrioid carcinoma,
which represent up to 80% of endometrial cancers and are usuallyally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1. The interaction between obesity and carcinogenesis.
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serous papillary, clear cell, or squamous cell subtypes and often
result from atrophic endometrial tissue in older women.13 There is
some evidence that endocrine and nutritional lifestyle factors,
including obesity, inﬂuence the risk of type I, but not of type II
cancers.11,12
Excess weight is associated with insulin resistance, which leads
to type II diabetes mellitus. In the insulin-resistant state, elevated
plasma insulin develops even during fasting. Insulin resistance
induced by overweight leads to a state of increased plasma con-
centration of fatty acids, which are released from adipose tissue.
The increase of free fatty acids leads to limitation of glucose ab-
sorption of liver and muscle for energy metabolism. These
cascading processes include a reduction of insulin receptor levels
and postreceptor defects in insulin signaling.14 Insulin resistance
and aberrant elevation of plasma insulin levels, in turn, lead to
various effects on the insulin growth factor (IGF) and insulin
growth factor-binding protein (IGFBP) system. These include de-
creases in the hepatic production and plasma levels of IGFBP-1 and
IGFBP-2, and a rise in plasma levels of free IGF-I. Plasma free IGF-I
correlates directly with BMI and levels of insulin, and inversely
with levels and IGFBP-1 and IGFBP-2.15 Epidemiological studies
have shown an increased risk of endometrial cancer in both pre-
and postmenopausal women with noninsulin-dependent diabetes.
One large caseecontrol study disclosed that endometrial cancer
risk to be associated with serum level of C-peptide a marker of
pancreatic insulin secretion.16 Several mechanisms have been
proposed to link the elevated insulin and endometrial cancer
development. Insulin can act as a growth factor and tumor tissues
including endometrial tumors, generally have an increased level of
IGF-I receptors.17 Furthermore, insulin can increase IGF-I activity in
endometrial tissue by suppressing gene expression of endometrial
IGFBP-1.18 Finally, insulin is also a major regulator of the sex hor-
mone binding globulin (SHBG). Downregulating SHBG level is a
direct determinant of bioavailable E2 unbound to SHBG.19 In a rat
model of hyperinsulinemia, estrogen induced higher expression of
the proliferative genes, including cyclin A and c-myc, in endome-
trium of obese rats, as compared with in lean ones.20 Adipose tissue
has been considered as a complex endocrine organ because it se-
cretes both anti- and proinﬂammatory factors classiﬁed as adipo-
kines. Tumor necrosis factor alpha (TNF-alpha), one of theimportant adipokines, disrupts insulin receptor signaling by
inducing the inhibitory phosphorylation of insulin receptor sub-
strate (IRS) proteins.21
The effect of obesity on endometrial cancer survival is not yet
well deﬁned. Higher prediagnosis BMI was signiﬁcantly associated
with poorer cancer-speciﬁc and overall survival in patients with
endometrial cancer reported from the result of the National In-
stitutes of Health-AARP Diet and Health Study.22 In a small study of
147 women with primary treatment of endometrial cancer in
Mexico, obese women had the same survival as normal or under-
weight women.23 In the endometrial cancer study of Women's
Health Initiative, no association has been observed between BMI
and disease stage or grade.24 Regarding the surgical outcome and
perioperative complications, obese patients have longer surgical
time, but intraoperative and overall postoperative complication
rates do not differ among different BMI.25,26 For women who are
moderately or severely obese receiving adjuvant radiotherapy for
endometrial cancer, a wider planning target margin is required to
reduce the magnitude of setup error.27 Furthermore, 4-year cancer-
speciﬁc survival in obese women (BMI 30 kg/m2) was 10% higher
than all-cause deaths, compared with 6% in nonobese women.28
Obesity and cervical cancer
The incidence of and mortality from cervical cancer have
decreased with the advent of the Papanicolaou test for cervical
cancer screening.29 It has been found that many cytokines and
chemokines play important roles in stimulating immune system to
regulate cervical carcinoma and integrate as a part of potential
cancer therapy.30 However, obese women in the United States were
reported to have a higher mortality from cervical cancer.5 A meta-
analysis review suggested that obese women were less likely to
report being screened for cervical cancer than their lean counter-
parts. Less screening may partly explain the higher cervical cancer
mortality seen in obese white women.31 Cervical adenocarcinoma
was found to be strongly associated with obesity rather than
squamous cell carcinoma. This ﬁnding implied that obesity may
have a particular inﬂuence on the risk of glandular cervical carci-
noma.32 Few data are available regarding treatment outcome of
patients with cervical cancer and obesity. For 404 women with
cervical cancer underwent deﬁnitive chemoradiation therapy,
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cervical cancer had diminished overall survival and more compli-
cations that normal weight and obese patients.33 Many gynecologic
oncologists believed that obese women are often poor candidates
for radical surgery, not only the perception of a more difﬁcult sur-
gical technique but also associated with increased rate of intra- and
postoperative complications. One study regarding completion
surgery after concurrent chemoradiation in obese women with
local advanced cervical cancer, the survival beneﬁt in individuals
with different BMIs was uncertain.34 In addition, the survival
beneﬁt was not compromised in patients with obesity and cervical
cancer treated with radical hysterectomy. The surgery in obese
patients was associated with longer duration of surgery and greater
blood loss.35,36 Without adequate evidence, obesity is not a nega-
tive prognostic factor in women with cervical cancer who under-
went surgery.
Obesity and ovarian cancer
Ovarian cancer is a highly fatal disease, with only 40% of women
with ovarian cancer alive >5 years after diagnosis. One of the rea-
sons contributing to the poor prognosis of ovarian cancer is that
approximately 75% of patients with ovarian cancer receive a diag-
nosis of metastatic spread beyond the pelvis.37 The rationale for
increased risk of ovarian cancer in women with obesity focuses on
the hormonal effect of obesity. In 2001, the International Agency for
Research on Cancer group found that the “evidence from the rela-
tively few studies has been inconsistent and does not allow any
conclusion to be drawn on a possible association”.38 However, a
30% increased risk of ovarian cancer in obese women (BMI of
>30 kg/m2) has been reported from a meta-analysis. It has been
hypothesized that in menopausal women, adiposity enhances
ovarian cancer risk partly through the mitogenic effects of excess
endogenous estrogen synthesized in the adipose tissue.39 Among
different histological subtypes of ovarian cancer, obesity was
positively associated with clear cell tumors, but less correlated with
invasive endometrioid or mucinous tumors.40 Few studies focused
on the association between obesity and ovarian cancer survival
provided conﬂicting results. A recent meta-analysis found that
womenwith ovarian cancer with obesity during early adulthood or
before diagnosis had worse survival.41 However, the effect of
obesity on surgical morbidity in primary ovarian cancer after
optimal primary tumor debulking remains controversial. Either
peri- or postoperative morbidity was not affected by BMI.42,43
However, in patients with ovarian cancer treated with
carboplatin-based chemotherapy, the carboplatin dosing is tradi-
tionally based on the Jelliffe formula, which lacks dose adjustment
for weight. Women with obesity experienced a lower relative
decrease in their platelet counts and hemoglobin levels. There was
a trend toward increased risk for disease progression in women
with a BMI  30.44
Obesity and breast cancer
There is growing evidence to link between obesity and breast
cancer. For postmenopausal women, prospective cohort studies
have associated increasing BMI with increasing breast cancer
incidence in postmenopausal women, especially in those with
hormone-positive breast cancer.45 Regarding the inﬂuence of
obesity and hormone replacement therapy on mammary carcino-
genesis, the strength of estrogenic risk attenuated by obesity is
stronger than with hormone replacement therapy. A review anal-
ysis showed that hormone replacement therapy does not increase
the risk of breast cancer in postmenopausal women with obesity
[relative risk (RR) 1.02 for BMI > 25 kg/m2], though it is a signiﬁcantrisk for breast cancer inwomen of normal weight (RR 1.73).46e48 By
contrast, studies of obesity and premenopausal breast cancer have
had conﬂicting results. Both prospective cohort and caseecontrol
studies in premenopausal women consistently report a modest
decreased risk of breast cancer in women with obesity compared
with women of normal weight, but with similar risks for women
with obesity and those of normal weight.49,50 However, a positive
association between increased BMI and premenopausal breast
cancer was found only in the Asia-Paciﬁc population.1 There is a
substantial body of research showing that obesity is a risk factor for
breast cancer recurrence and poor survival. A meta-analysis esti-
mated overweight or obese was associated with a 78e91%
increased risk of recurrence and a 36e56% increased risk of death in
womenwith breast cancer. A detailed review by Chlebowski et al51
concluded that a signiﬁcant association between being obese and
increased recurrence or mortality was seen in 26 of 40 studies
including 29,460 women with breast cancer.51 The effect of obesity
on clinical presentation and detection was investigated by a
retrospective review. It was disclosed that womenwith obesity that
is clinically present at an older age with mammographically
detected breast cancer at more advance stages than women
without obesity.52 In recent caseecase analyses within a large
consortium, obesity was more frequent with hormone receptor
negative than hormone receptor positive disease in women
younger than 50 years, but was more frequent only with proges-
terone receptor-positive tumor in older women.53 Triple-negative
breast cancer is a subtype of breast tumor with unique character-
istics in terms of clinical-pathological presentation, response to
therapy, and poor outcome. By a caseecase comparison from a
systemic review, a signiﬁcant association between triple-negative
breast cancer and obesity was identiﬁed (odds ratio: 1.20; 95%
conﬁdence interval: 1.03e1.40).54
Several studies have investigated the interactions between
obesity and adjuvant therapy effectiveness. A National Surgical
Adjuvant Breast and Bowel Project analysis of 3385 clinical trial
patients from a randomized, placebo-controlled trial evaluating
tamoxifen for lymph node-negative, estrogen receptor-positive
breast cancer showed that women with obesity had greater all-
cause mortality and increased risk of contralateral breast cancer
compared with women of normal weight.55 Chemotherapy is one
of the important treatments in breast cancer patients to improve
survival. From a retrospective review of 735 patients with stages II
and III primary breast cancer, patients with obesity tended to have a
higher risk of disease recurrence after receiving adjuvant chemo-
therapy.56 However, in metastatic breast cancer, BMI was not
associated with outcome of patients treated with ﬁrst-line
chemotherapy from a recent retrospective trial report.57Conclusion
Obesity has become an emerging challenge in human diseases
including malignancy. However, it is not surprising that in no
circumstance was obesity found to exert a positive beneﬁt. With
increasing evidence of the effect of obesity in gynecological ma-
lignancy, the better approach to prevent and manage obesity-
related gynecological malignancy should be addressed in the
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